

# Katia Pagnano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1425170/publications.pdf>

Version: 2024-02-01

127  
papers

1,133  
citations

471061

17  
h-index

476904

29  
g-index

130  
all docs

130  
docs citations

130  
times ranked

1650  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. <i>Haematologica</i> , 2007, 92, 1431-1432.  | 1.7 | 131       |
| 2  | Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , 2013, 121, 1935-1943.   | 0.6 | 96        |
| 3  | Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010. | 0.8 | 58        |
| 4  | Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. <i>Clinical Chemistry</i> , 2013, 59, 938-948.  | 1.5 | 46        |
| 5  | p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. <i>American Journal of Hematology</i> , 2001, 67, 84-92.   | 2.0 | 43        |
| 6  | Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort. <i>Acta Haematologica</i> , 2013, 130, 16-22.  | 0.7 | 34        |
| 7  | All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.   | 0.8 | 31        |
| 8  | Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 538-542.   | 1.3 | 30        |
| 9  | High $\hat{P}^{73}/TAp73$ ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2302-2306.   | 0.6 | 28        |
| 10 | Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 728-733.  | 0.2 | 26        |
| 11 | Current patient management of chronic myeloid leukemia in Latin America. <i>Cancer</i> , 2010, 116, 4991-5000.  | 2.0 | 23        |
| 12 | Mutations in the p53 Gene in Acute Myeloid Leukemia Patients Correlate with Poor Prognosis. <i>Hematology</i> , 2002, 7, 13-19.   | 0.7 | 22        |
| 13 | Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.   | 0.6 | 21        |
| 14 | Apoptosis-Regulating Proteins and Prognosis in Diffuse Large B Cell Non-Hodgkin's Lymphomas. <i>Acta Haematologica</i> , 2002, 107, 29-34.  | 0.7 | 19        |
| 15 | Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience. <i>Clinics</i> , 2015, 70, 550-555.  | 0.6 | 19        |
| 16 | Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 71-89.  | 0.7 | 18        |
| 17 | Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients – An analysis from the Brazilian Hodgkin Lymphoma Registry. <i>International Journal of Cancer</i> , 2018, 142, 883-890.  | 2.3 | 17        |
| 18 | COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. <i>Blood</i> , 2020, 136, 46-47.   | 0.6 | 17        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience. Sao Paulo Medical Journal, 2000, 118, 173-178.   | 0.4 | 15        |
| 20 | Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. Leukemia, 2009, 23, 144-152.   | 3.3 | 15        |
| 21 | BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Investigation, 2015, 33, 451-458.   | 0.6 | 15        |
| 22 | BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. Cell Death and Disease, 2017, 8, e3114-e3114.  | 2.7 | 15        |
| 23 | Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. Hematological Oncology, 2018, 36, 189-195.  | 0.8 | 15        |
| 24 | Frontline Therapy with Early Intensification and Autologous Stem Cell Transplantation versus Conventional Chemotherapy in Unselected High-Risk, Aggressive Non-Hodgkin's Lymphoma Patients: A Prospective Randomized GEMOH Report. Acta Haematologica, 2006, 115, 15-21.   | 0.7 | 14        |
| 25 | Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 211-215.  | 0.7 | 14        |
| 26 | Philadelphia-negative chronic myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 140-149.  | 0.7 | 14        |
| 27 | Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib. Hematology, 2014, 19, 31-41.   | 0.7 | 13        |
| 28 | Prognostic impact of <i>KMT2E</i> transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. British Journal of Haematology, 2014, 166, 540-549. | 1.2 | 13        |
| 29 | Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 162-166.   | 0.2 | 13        |
| 30 | New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 2009, 50, 1148-1154.  | 0.6 | 12        |
| 31 | JAK2 46/1 haplotype is associated with <i>JAK2</i> V617F positive myeloproliferative neoplasms in Brazilian patients. International Journal of Laboratory Hematology, 2015, 37, 654-660.   | 0.7 | 12        |
| 32 | Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center. Hematology, Transfusion and Cell Therapy, 2019, 41, 125-128.   | 0.1 | 12        |
| 33 | Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Advances, 2021, 5, 4855-4863.  | 2.5 | 11        |
| 34 | Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. Blood, 2009, 114, 6-6.   | 0.6 | 11        |
| 35 | Molecular characteristics and chromatin texture features in acute promyelocytic leukemia. Diagnostic Pathology, 2012, 7, 75.   | 0.9 | 10        |
| 36 | Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting. Blood, 2015, 126, 1863-1865.   | 0.6 | 10        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up. <i>Oncology Letters</i> , 2016, 12, 485-487.   | 0.8 | 10        |
| 38 | Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 57, 54-57.   | 0.6 | 10        |
| 39 | BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution. <i>Acta Haematologica</i> , 2015, 134, 248-254. | 0.7 | 9         |
| 40 | Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. <i>Blood</i> , 2017, 130, 900-900.  | 0.6 | 9         |
| 41 | JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia. <i>Genetics and Molecular Biology</i> , 2007, 30, 336-338.  | 0.6 | 9         |
| 42 | Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. <i>Clinics</i> , 2013, 68, 339-343.  | 0.6 | 9         |
| 43 | Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1807-1814.  | 2.5 | 8         |
| 44 | Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 329-334.  | 0.1 | 8         |
| 45 | Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (<sc>EDI&PIO</sc>) in chronic myeloid leukemia with deep molecular response. <i>American Journal of Hematology</i> , 2020, 95, E321-E323.   | 2.0 | 8         |
| 46 | Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2014, 55, 1861-1869.   | 0.6 | 7         |
| 47 | Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , 2020, 12, 3134.   | 1.7 | 7         |
| 48 | Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 367-382.  | 0.7 | 7         |
| 49 | Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 60, 74-77.   | 0.6 | 6         |
| 50 | COVID-19 in chronic myeloid leukemia patients in Latin America. <i>Leukemia and Lymphoma</i> , 2021, 62, 3212-3218.   | 0.6 | 6         |
| 51 | Philadelphia-positive B-lymphoblastic leukemia in a middle-income country – A real-world multicenter cohort. <i>Leukemia Research</i> , 2021, 110, 106666.  | 0.4 | 6         |
| 52 | STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. <i>Investigational New Drugs</i> , 2022, 40, 438-452.   | 1.2 | 6         |
| 53 | The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). <i>Hematology</i> , 2012, 17, s36-s38.  | 0.7 | 5         |
| 54 | NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 10315.   | 1.6 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials. <i>Blood</i> , 2019, 134, 1655-1655. | 0.6 | 5         |
| 56 | COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. <i>Blood</i> , 2021, 138, 634-634.                         | 0.6 | 5         |
| 57 | Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 449-454.                                    | 1.4 | 4         |
| 58 | Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 58-74.  | 0.7 | 4         |
| 59 | BCR-ABL1 level monitoring in chronic myeloid leukemia by real time polymerase chain reaction in Brazil "not so real". <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 197-198.  | 0.7 | 4         |
| 60 | Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7009-7009.   | 0.8 | 4         |
| 61 | Metabolic shift of chronic myeloid leukemia patients under imatinib "pioglitazone regimen and discontinuation. <i>Medical Oncology</i> , 2021, 38, 100.  | 1.2 | 4         |
| 62 | Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study. <i>Blood</i> , 2018, 132, 46-46.  | 0.6 | 4         |
| 63 | Pioglitazone Did Not Affect PPAR- $\alpha$ , STAT5, HIF1 $\alpha$ and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response. <i>Blood</i> , 2019, 134, 1637-1637.   | 0.6 | 4         |
| 64 | EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience. <i>Blood</i> , 2012, 120, 1681-1681.       | 0.6 | 4         |
| 65 | Apoptotic cells in a peripheral blood smear in the context of EBV infection. <i>American Journal of Hematology</i> , 2001, 67, 148-149.  | 2.0 | 3         |
| 66 | Guideline on myeloproliferative neoplasms: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 1-73.  | 0.1 | 3         |
| 67 | Toll-like receptor gene polymorphisms in patients with myeloproliferative neoplasms. <i>Molecular Biology Reports</i> , 2021, 48, 4995-5001.   | 1.0 | 3         |
| 68 | B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line. <i>Blood</i> , 2018, 132, 1749-1749.   | 0.6 | 3         |
| 69 | Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET). <i>Blood</i> , 2019, 134, 554-554.  | 0.6 | 3         |
| 70 | Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. <i>Clinics</i> , 2011, 66, 793-9.   | 0.6 | 3         |
| 71 | Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol. <i>Advances in Hematology</i> , 2010, 2010, 1-3.  | 0.6 | 2         |
| 72 | Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 247-251.  | 0.7 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 915-918.              | 1.2 | 2         |
| 74 | Evaluation Of Seasonality In The Incidence Of Promyelocytic Leukemia In Brazil. <i>Blood</i> , 2013, 122, 5005-5005.   | 0.6 | 2         |
| 75 | Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study. <i>Blood</i> , 2019, 134, 5844-5844.  | 0.6 | 2         |
| 76 | Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019, 134, 2938-2938.   | 0.6 | 2         |
| 77 | Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 195-199.                               | 0.1 | 1         |
| 78 | High Adherence to Tyrosine Kinase Inhibitors Seems to Be Related to Best Cytogenetic Responso In the Hasford Lower Risk Graup In Chronic Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 4477-4477.                                 | 0.6 | 1         |
| 79 | Primary Myelofibrosis Brazilian Patient Journey: From Initial Symptoms To Treatment. <i>Blood</i> , 2013, 122, 5255-5255.  | 0.6 | 1         |
| 80 | Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Blood</i> , 2015, 126, 4031-4031.   | 0.6 | 1         |
| 81 | Chromatin Texture and Molecular Features Are Independent Prognostic Factors In AML. <i>Blood</i> , 2010, 116, 4850-4850.   | 0.6 | 1         |
| 82 | Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 33, 432-438. | 0.7 | 1         |
| 83 | Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitorsâ€“ A Study on Behalf of Latin American Leukemia Net (Lalnet). <i>Blood</i> , 2011, 118, 1701-1701.            | 0.6 | 1         |
| 84 | Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses. <i>Blood</i> , 2012, 120, 3787-3787.            | 0.6 | 1         |
| 85 | Evaluation Of hOCT1expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line. <i>Blood</i> , 2013, 122, 4041-4041.  | 0.6 | 1         |
| 86 | Predictive Value Of Early Molecular Responses In Outcomes Of Patients With Chronic Myeloid Leukemia Treated With Imatinib In First-Line Therapy. <i>Blood</i> , 2013, 122, 4941-4941.  | 0.6 | 1         |
| 87 | Improving the Outcomes of Acute Promyelocytic Leukemia in a Limited Resources Setting: The Benefit of Early ATRA Administration in 30-Day Survival. <i>Blood</i> , 2018, 132, 5874-5874.   | 0.6 | 1         |
| 88 | Final Results of the Fibromet Trial: An Open Label Phase II Study to Evaluate Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients. <i>Blood</i> , 2021, 138, 2584-2584.          | 0.6 | 1         |
| 89 | MÃ“ltiplas infecÃ§Ã“es oportunistas em um paciente com leucemia linfocÃ“tica crÃ“nica tratado com cladribina. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2000, 22, 420.  | 0.7 | 0         |
| 90 | Os desafios no tratamento da Leucemia mielÃ“ide crÃ“nica na era do mesilato de imatinibe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2004, 26, 282.  | 0.7 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017, 1, 86-89.   | 2.5 | 0         |
| 92  | Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country. <i>Blood Advances</i> , 2017, 1, 80-83.   | 2.5 | 0         |
| 93  | Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 101-102.  | 0.1 | 0         |
| 94  | Challenges in Chronic Myeloid Leukemia Management in South America. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 440-447.  | 1.2 | 0         |
| 95  | High-Dose Sequential Chemotherapy Versus a Less Intensive Chemotherapeutic Regimen Followed by Peripheral Blood Progenitor Cell Autografting in Patients with Advanced Hodgkin's Disease.. <i>Blood</i> , 2005, 106, 5485-5485.   | 0.6 | 0         |
| 96  | Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib.. <i>Blood</i> , 2006, 108, 4817-4817.   | 0.6 | 0         |
| 97  | Screening of Mutations in BCR-ABL Kinase Domain in Chronic Myeloid Leukemia (CML) Patients Treated with Kinase Inhibitors by Denaturing High-Performance Liquid Chromatography (D-HPLC).. <i>Blood</i> , 2007, 110, 4580-4580.  | 0.6 | 0         |
| 98  | Brazilian Experience Using High Dose Sequential (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (AH SCT) for Relapse/Refractory Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 5102-5102.   | 0.6 | 0         |
| 99  | High Dose Sequential (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (AH SCT) for Salvage Treatment of Hodgkin's Disease (HD): A Brazilian Experience.. <i>Blood</i> , 2007, 110, 5103-5103.   | 0.6 | 0         |
| 100 | Janus Kinase (JAK2) V617F Somatic Mutation in Patients with Deep Vein Thrombosis.. <i>Blood</i> , 2007, 110, 1645-1645.   | 0.6 | 0         |
| 101 | The Gene RUNX1 and Its Possible Relation with the Alteration of Granulocytes Cells and with the Progression of Chronic Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2215-2215.  | 0.6 | 0         |
| 102 | Impact of Imatinib Dose Escalation in Chronic Myeloid Leukemia Patients in Chronic Phase with Sub-Optimal Response or Failure with Imatinib 400 Mg.. <i>Blood</i> , 2009, 114, 3289-3289.   | 0.6 | 0         |
| 103 | Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.. <i>Blood</i> , 2009, 114, 3260-3260.  | 0.6 | 0         |
| 104 | Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience.. <i>Blood</i> , 2011, 118, 3552-3552.  | 0.6 | 0         |
| 105 | $\hat{P}^{73}$ Np73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia.. <i>Blood</i> , 2011, 118, 3536-3536.   | 0.6 | 0         |
| 106 | The Alteration of SEPT5 Gene Expression in BCR-ABL Positive Cells and Its Possible Correlation with the Development and / or Progression of Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2011, 118, 4415-4415.  | 0.6 | 0         |
| 107 | Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> . 2012. 120. 1407-1407. | 0.6 | 0         |
| 108 | The Relationship Between the Regulation of TOB1 Gene with Cell Proliferation, Apoptosis and Cell Cycle in BCR-ABL Positive Cells. <i>Blood</i> , 2012, 120, 5125-5125.  | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors. <i>Blood</i> , 2013, 122, 5189-5189.   | 0.6 | 0         |
| 110 | Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment. <i>Blood</i> , 2013, 122, 1326-1326.   | 0.6 | 0         |
| 111 | Evaluation Of Anemia After Long-Term Treatment With Imatinib In Chronic Myeloid Leukemia In Chronic Phase. <i>Blood</i> , 2013, 122, 5200-5200.   | 0.6 | 0         |
| 112 | Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , 2013, 122, 2586-2586. | 0.6 | 0         |
| 113 | Feasibility of Implementing Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Patients Treated in Developing Countries. <i>Blood</i> , 2014, 124, 5354-5354.  | 0.6 | 0         |
| 114 | Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study. <i>Blood</i> , 2015, 126, 5032-5032.   | 0.6 | 0         |
| 115 | Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg. <i>Blood</i> , 2016, 128, 1911-1911.  | 0.6 | 0         |
| 116 | Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. <i>Blood</i> , 2018, 132, 1533-1533.   | 0.6 | 0         |
| 117 | Metformin treatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. <i>Blood</i> , 2018, 132, 1532-1532.   | 0.6 | 0         |
| 118 | Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 2719-2719.  | 0.6 | 0         |
| 119 | Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 5166-5166.  | 0.6 | 0         |
| 120 | Using Antigen Expression of Leukemic Cells for a Fast Screening of Acute Promyelocytic Leukemia by Flow Cytometry. <i>Diagnostics</i> , 2021, 11, 1988.   | 1.3 | 0         |
| 121 | Clinical Significance of Mitochondrial DNA Content in Acute Promyelocytic Leukemia. <i>Blood</i> , 2021, 138, 3474-3474.  | 0.6 | 0         |
| 122 | The Importance of Bone Marrow Lymphocyte Subtypes As Predicting Factors for Molecular Recurrence in Patients with Chronic Myeloid Leukemia after Discontinuation of Imatinib. <i>Blood</i> , 2021, 138, 2564-2564.  | 0.6 | 0         |
| 123 | A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients. <i>Blood</i> , 2021, 138, 4601-4601.  | 0.6 | 0         |
| 124 | Developing a Simple Algorithm Based on Multiparameter Flow Cytometry for Fast Screening of Acute Promyelocytic Leukemia. <i>Blood</i> , 2020, 136, 25-26.   | 0.6 | 0         |
| 125 | COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience. <i>Blood</i> , 2020, 136, 48-49.  | 0.6 | 0         |
| 126 | Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, , .  | 0.1 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel. Hematology, Transfusion and Cell Therapy, 2022, , . | 0.1 | 0         |